mTOR inhibition augments antitumor immune effector response by reprogramming the TP53-mutant, immune-cold HNSCC tumor microenvironment.

Authors

Priyatosh Nath, Alok Khandelwal, Chun Li, Tara Moore-Medlin, Srivatsa Surya Vasudevan, Victor Albornoz Alvarez, Omar E Franco, J Silvio Gutkind, Cherie-Ann O Nathan

Published in

Neoplasia (New York, N.Y.). Volume 80. Pages 101350. Aug 08, 2026. Epub Aug 08, 2026.

Abstract

Resistance to immunotherapy remains a major clinical challenge in TP53-mutant head and neck squamous cell carcinoma (HNSCC), a disease subset characterized by immune exclusion, high recurrence, and poor outcomes. Given the constitutive activation of PI3K/AKT/mTOR signaling in TP53-mutant HNSCC and its role in disease progression, we investigated whether the mTOR inhibition (mTORi) could overcome immune resistance and improve outcomes. We evaluated the effects of mTOR inhibitor everolimus in tumor microenvironment (TME) changes, including immune cell infiltration, immune checkpoint expression, and key pathways associated with immune suppression and angiogenesis, to define the mechanisms underlying TME remodeling. Everolimus significantly suppressed tumor growth in syngeneic HNSCC models. At the cellular level, everolimus significantly increased intratumoral CD8+ T cell and dendritic cell (DC) infiltration while reducing regulatory T cell (Treg) accumulation. Mechanistically, everolimus induced a cytokine/chemokine response, marked by increased TNF-α/CXCL10 expression, leading to enhanced immune infiltration. Everolimus also inhibited the HIF-1α/VEGFA pathway, a central driver of immune exclusion and myeloid-derived suppressor cell (MDSC) recruitment. Furthermore, everolimus treatment attenuated PD-1/PD-L1 signaling by reducing PD-1 and PD-L1 expression in T cells and tumor cells, thereby restoring T-cell cytotoxic competence. These findings demonstrate that mTORi with everolimus reverses multiple mechanisms of immune resistance and enhances anti-tumor T cell activity. Collectively, these results support mTORi as a rational therapeutic strategy for TP53-mutant HNSCC and for reprogramming the immune-resistant TME, particularly in patients who are likely to fail immunotherapy.

PMID:
42570420
Bibliographic data and abstract were imported from PubMed on 09 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.